Haemoglobin (Hb) in the adult human consists of predominantly HbA, with a small amount of HbA 2, and a trace of HbF. HbA contains a number of minor haemoglobins identified as HbA la, HbA 1b, and HbA!c, collectively referred to as HbA l, 'fast haemoglobins', glycosylated or glycated haemoglobins or simply glycohaemoglobins. The first description of fast haemoglobin was made by Kunkel and Wallenuis' in 1955. These workers were using starch gel electrophoresis to separate haemoglobin in the blood of diabetics, and identified the fast fraction as 'new' haemoglobins. For more than a decade methods used to isolate HbA I were based on ion exchange chromatography; Allen and co-workers? in 1958, described a cation exchange column that was capable of separating the fast fraction. Under modified conditions this method could further separate this fraction into HbA 1a, HbA 1b, and HbA le. It was confirmed in 1961 that these fractions were all contained in the fast electrophoretic fraction.! In 1957, Rhinesmith and co-workers'> suggested that there was some abnormality present in the N-terminus of the fJ chain of HbA\. Most of the attention to the structural characterization was given to HbA le, which constitutes the major portion of the fast haemoglobins. Holmquist and Schroeder" in 1966, concluded that HbA le is a condensation product (Schiff base) of HbA and a ketone or an aldehyde (R = 0). The point of linkage of R = 0 to the haemoglobin was the N terminus of the fJ chain. The investigations of Bookchin and Gallop? strongly indicated that a hexose was linked to the Nterminal valine of the f1 (Ale) chain. The exact nature of the hexose molecules was elucidated by Bunn and co-workers" who were able to isolate the reducing sugars by mild acid hydrolysis and showed them to be glucose and mannose in a This article was prepared under the auspices of the Analytical Investigations Standing Committee of the Scientific Committee of the Association of Clinical Biochemists. ratio of 3:1. These workers also suggested that the second carbon atom rather than the first was reduced. Glucose probably reacts initially with the amino terminus to form an aldamine linkage that subsequently undergoes an Amadori rearrangement? to form a stable ketoamine.
Treatment of HbA le with tritiated borohydride and isolation of the terminal glycopeptide I-deoxy-l (N-valyl)-fructose, supported the evidence of an Amadori rearrangement.l? and indicated that the extent of Amadori rearrangement of newly synthesized HbA 1e was 60% by 6 days and 91 % by 22 days, Evidence that glucose is present in the ring form came from studies using antibodies against native HbA le which showed a much weaker binding to borohydride-reduced HbA le in which the glucose is present in an open form. 11
The nature of the glycation process The findings of several groups of workers have indicated the non-enzymatic nature of the glycation process. Synthesis of HbA le is very slow and dependent on the level of glycaemia. 12 , 13 Using 59Fe as a marker, it was found that radioactivity was incorporated into HbA le throughout the life span of both mouse'? and human red cells.'? Further observations indicated that HbA I was decreased in haemolytic anaemia.P and highest concentrations occurred in the oldest red cells of both normal and diabetic subjects. 14 The non-enzymatic nature of the reaction was further supported by the observations that crude haemolysate or purified (enzyme-free) HbA o was glycated at the same rate," and by the fact that synthetic L-(l4C) glucose reacted as well as the natural D-(l4C) glucose isomer. 16 Mortensen and Christophersen'? suggested that the Amadori rearrangement forming the ketoamine is reversible, These workers used isoelectric focusing to isolate and quantify HbA 1e, and based their argument on the findings that HbA o can be regenerated during prolonged saline incubation of HbA le.
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The binding of glucose with the amino terminus of the {J-chain of haemoglobin is the reaction favoured in vivo. However, other aldoses (galactose, maltose, lactose) form haemoglobin adducts at least in vitro l 8 and other amino groups (ex-chain amino terminus, variouss-amino groups on both ex-and {J-chain) are glycated both in vivo and in vitro.t"
CLINICAL RELEVANCE
The major treatment objectives III diabetes mellitus have been the alleviation of hyperglycaemic symptoms and the prevention of longterm microvascular and macrovascular complications. The surveillance of glycaemic control in diabetic patients has vastly improved since the introduction of methods for the measurement of glycated haemoglobin. A series of studies'P-" have confirmed the utility of glycated haemoglobin measurements as a monitor of glucose control in patients with insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus. It was demonstrated in 1976, that when patients with insulin-dependent diabetes mellitus were brought under control in hospital, it took 8 to 12 weeks for the elevated glycated haemoglobin concentrations to return to normal." Thus, the concept that a single glycated haemoglobin determination reflects the average serum glucose concentration for the preceding 8-12 weeks was established.
NOMENCLATURE
In 1978 the term glycosylated haemoglobin was introduced to refer to the product of the nonenzymatic reaction between glucose and the free amino groups of haemoglobin.P The IUPAC-IUB Joint Commission on Biochemical Nomenclature" recommends that glycation, which refers to any carbohydrate-protein linkage regardless of structure or mode of synthesis, be used in preference to glycosylation, which refers specifically to the addition of glucose. The term glycated haemoglobin has thus become widely accepted. Confusingly, an alternative, glycohaemoglobin," has been proposed and is used in some journals: a glycoprotein is generally defined as a protein species which has been enzymatically modified to incorporate carbohydrate moieties. Haemoglobin AI (HbA 1 ) refers to all species derived from adducts (not necessarily glucose) to the N-terminal valine of haemoglobin, whereas haemoglobin Ale (HbA 1e) is a specific adduct of glucose to the N-terminal valine of haemoglobin, which is the preferred site of binding. HbA le usually constitutes 60%-80% of HbA 1 , the remainder being adducts with fructose 1,6-diphosphate (HbA 1al), glucose-6phosphate (HbA 1a2 ) and an unknown carbohydrate (HbA 1b ) , not of direct importance in diabetic monitoring. Total glycated haemoglobin includes (in analytical terms) HbA le and the species derived from glucose adducts at secondary sites, i.e. amino groups elsewhere in the haemoglobin molecule.
METHODOLOGY
The addition of glucose to haemoglobin creates a number of changes in that molecule. A number of these differences have been utilized in the various methods developed for the estimation of glycated haemoglobin (Table 1) .
Chromatographic procedures

Cation exchange chromatography
Chromatographic procedures were used in the late 1950s 2 for the separation of minor haemoglobin components. These methods were cumbersome and time consuming using long HbA ' b fractions from the column. The significant problems of poor reproducibility encountered with earlier methods was addressed by using tri-Ievel calibrators to correct for temperature, pH etc. The method was widely used in mainland Europe, but little used in the UK. Overall the number of laboratories using this method is now decreasing.
High-performance liquid chromatography
High-performance liquid chromatography (HPLC) methods were described as early as 1978. 25.26 These methods employed cation exchange resin, displayed good resolution, were rapid (20-30 min), and gave acceptable reproducibility [5%-10% coefficient of variation (CV)]. Automated HPLC methods were first described the following year,27.28 and these displayed excellent within-and between-batch precision.
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The increasing numbers of glycated haemoglobin requests received by laboratories has resulted in the need for increased automation, shorter turnaround time, and high sample throughput. Dedicated HPLC systems have become commercially available for the estimation of HbAdHbA1e, although non-dedicated systems adapted to the analysis of glycated haemoglobin are becoming more widely available. Dedicated HPLC instruments are available from a number of manufacturers, and their analytical performance has recently been reviewed." There is currently available one low pressure, and several high pressure cation exchange resin systems.
Low pressure system. The Glycomat analyser and its successor the Hb Gold are manufactured by Drew Scientific (Barrow in Furness, UK) and distributed by Ciba Coming Diagnostics (Halsted, UK) and Biomen Ltd (Finchampstead, UK), respectively. These systems utilize a binary gradient and mini-columns, each capable of performing at least ISO separations before it has to be changed. The instrument will give results as HbA 1 and HbA\e and may be adjusted for the estimation of HbA 2, HbF and HbS.
High pressure system. There are several systems available. Optimized systems for separation of HbA 'e are at present recognized as the reference technique. The fully automated Diamat and Variant Analysers distributed by Bio Rad (Hemel Hempstead, UK) still requires sample pre-treatment before loading onto the autosampler. The analyser utilizes a tertiary gradient and produces HbA[ and HbA\e results. The Diamat and Variant results are not obtained directly from the peak areas, but are calculated from comparison with calibrant chromatograms stored in the instrument; this is necessary to correct for peak broadening as the column ages. The Shimadzu HPLC haemoglobin System (UK Distributor Dyson Instruments, Houghton-Ie-Spring, UK) also corrects the results obtained after comparison with calibration chromatograms; but unlike the BioRad instruments this system uses a binary elution gradient. The greatest degree of automation is shown by the Daiichi Hi-Auto Ale, HA 8121 and HA 8140 analysers (UK distributor Biomen Ltd, Finchampstead, UK). These analysers have the ability to dilute, haemolyse and remove the Schiff base automatically within the analyser. Removal of the Schiff base is achieved by incubation with tetrapolyphosphate (pH 6'0) for 2 min at 48°C in a thermal-jacketed loop. Analysis time including these additional stages is 4 min. Unlike the HA 8121, the HA 8140 has the ability to measure HbA le in the presence of abnormal haemoglobins.
Affinity chromatography
Affinity separation of glycated haemoglobin was first described by Mallia and co-workers in 198],30 The method which utilizes m-aminophenyl boronic acid depends on a specific interaction between glycated haemoglobin and the immobilized boronate anion. In aqueous solution, boronic acid ionizes from a co-planar, trigonal form into a tetrahedral anion. In this latter form, the borate can produce a reversible covalent complex with vicinal hydroxyl groups ( Fig. I) . Because of the short boron-oxygen bond length," interaction with coplanar diol groups in the cis configuration is greatly favoured.
Glycated haemoglobin contains coplanar cisdiol groups and interacts strongly with boronic acid immobilized on an agarose gel. Ionic and hydrophobic forces also contribute to this interaction.P-F After elution of the non-glycated fraction, bound haemoglobin can be dissociated by the use of a counter-ligand (sorbitol) which effectively competes with bound glycated haemoglobin for the boronic acid sites on the gel surface. The absorbance of the haemoglobin fractions can be measured at 414 nm and the percentage calculated.
The affinity chromatography method has been extensively investigated by a number of workers. n --3s It is not significantly affected by temperature.r' uraemia." fetal haemoglobin.t? or by the labile Schiff base." Results correlate well with HPLC, electroendosmosis, and ion a::: CHzOH exchange chromatography." It has been found to display good within-laboratory precision, but between-laboratory agreement is less satisfactory." In addition, Wettre and Von Schenck'? reported batch to batch variation in ligand concentration, which resulted in significant variation in results obtained.
The recently introduced Primus analyser (UK distributor Gamidor Ltd, Abingdon, UK) combines the properties of affinity separation with the speed and convenience of HPLC. Separation of glycated and non-glycated haemoglobin is achieved using affinity chromatography as above, analysis time being only 2 min, the column being regenerated between each analysis. The method shows good within and between-batch precision; as the method is relatively new, there is limited information available relating to variation in ligand concentration in different batches of affinity gel.
The boronate affinity principle has been adapted for use with the Abbott Vision™ System for the determination of glycated haemoglobin. The Vision instrument is a clinical chemistry analyser that uses two-dimensional centrifugation to measure, transport and combine specimens and reagents within a disposable test pack. The method evaluation'? showed good reproducibility, a high degree of correlation with other methods and no interference by the labile fraction, abnormal haemoglobins or other compounds likely to interfere. It is unfortunate that the system, which employs affinity separation to measure glycated haemoglobin, corrects the results obtained to %HbA 1e , by using standards whose values have been assigned by HPLC. As outlined above these fractions are related, but are not the same.
The affinity assay on the Abbott IMx ™ analyser utilizes a separation technology based on polyelectrolyte interaction." The glass fibre matrix of the IMX disposable reaction cell is pre-coated with a high-molecular-mass quaternary ammonium compound. This imparts a net positive charge to the matrix, which enables electrostatic capture of anionic analyte-carrier complexes. These complexes are formed between molecules of glycated haemoglobin and polyanionic affinity reagent composed of polyacrylic acid and dihydroxy boronate. Glycated haemoglobin is separated from non-glycated haemoglobin through the electrostatic interaction between the polyacrylic acid component of the affinity reagent and the cationic solid phase (Fig. 2) . Glycated haemoglobin is quantified by
Polyanionic affinity reagent
A commercial kit (CIBA Corning, Halstead) incorporating electroendosmosis methodology compared favourably with a short-column chromatographic method.?' This kit was also shown to compare well with a reference HPLC method. Unlike ion-exchange chromatography, electroendosmosis was not significantly affected by fluctuations in temperature. Additionally the method, with modification of the electrophoretic time, appeared capable of detecting glycated HbS and HbC. As with column procedures, the method could not be used in the presence of significant levels of HbF as this haemoglobin has the same electrophoretic mobility as HbA j . This method was the most popular method used for estimating HbA I in the UK during the 1980s due to the ease of use, along with good precision (at that time) and insensitivity to pH and temperature variations. The popularity of the methods' is now decreasing as it has been superseded by more precise assays with higher throughput that are also less labour-intensive. 
Agar gel electroendosmosis
Glycation of haemoglobin at the N-terminal valine changes its isoelectric point by only 0·01 of a pH unit. 42 It is not surprising therefore that conventional electrophoretic techniques have not proved suitable for the assay of HhA], In 1980 Menard and co-workers'? described a method using agar gel plates and a citrate buffer, on which separation of HbA I can be achieved by electroendosmosis. Haemoglobin Ao, being more positively charged than HbA!, interacts more strongly with the fixed negative charge of the gel matrix, while the HbA I is swept towards the cathode by the electroendosmotic flow of buffer. The resulting bands can be measured using a scanning densitometer at a suitable wavelength (usually 420 nm). Most instruments give a visual peak display in addition to a direct readout of the percentage haemoglobin that is HbA I .
Agarose electrophoresis
Recent years have seen improvements in electrophoretic methods. Agar systems have been replaced by agarose gels (Diatrac; Beckman) and electrophoretic methods have been automated (REP automated electrophoresis instrument; Helena Laboratories). These modern systems allow for the separation of HbA lc in the presence of abnormal haemoglobins. The REP system has good precision with a high degree of automation." These methods are not sensitive to temperature or pH variation, but they do have a long analytical time. Undoubtedly, these methods are a significant improvement over previous electrophoretic methods, but are of limited use when a high sample throughput is required.
Immunoassay
Enzyme immunoassay
Recently an enzyme immunoassay (EIA) was introduced into clinical use (NovoClone'P", Dako Diagnostics Ltd, Ely, UK). 47 The method uses a monoclonal antibody raised against HbA 1c , which recognizes the first eight amino acids on the fJ-chain plus the attached glucose. Red cells in the sample are haemolysed, the haemoglobin oxidized and the pH adjusted to optimize binding to a microtitre plate. Unbound haemoglobin is removed by washing. The monoclonal antibody-enzyme conjugate binds other analysers." Due to the utilization of high specificity antibodies, the method does not cross-react with HbA o , HbA 1 ., HbA 1h , acetylated haemoglobin, carbamylated haemoglobin or Schiff base. Additionally, as the antibody recognizes the first four amino acids no interference should be seen with HbS or HbC.
A similar immunoturbidimetric method has recently been introduced by Roche Diagnostic Systems (Welwyn Garden City, UK). This method includes pepsin in the lysing reagent, the proteolytic degradation making the f3-Nterminal structure more accessible for the HbA)c immunoassay. Total haemoglobin is measured using a cyanide free colorimetric method based on the formation of alkaline hematin D-575, a brown-green chromophore. This method utilizes an antibody which recognizes the first three amino acids on the fJ-chain of the haemoglobin so, again, there should be no interference with HbS or HbC.
Although, theoretically, neither HbS nor HbC should affect these immunoturbidimetric methods, there may be an affect with the Roche
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to HbA 1c immobilized on the plate and any unbound conjugate is removed by washing. Horseradish-peroxidase on the bound conjugate is reacted with the substrate 3,3',5,5'-tetramethylbenzidine (TMB) to produce a colour. The reaction is stopped with acid and the colour intensity measured at 450 nm using a microtitre plate reader. Readings are related to calibrators of known percentage HbA 1c (assigned by HPLC). The method was found to be reproducible and to correlate well with other methods." The reference range for this method (2,8%--4,9% HbA 1c ) is lower than that found with other HbA 1c methods. This may be due to the high specificity of the antibody, or to the secondary calibration of the method. The antibody used in this method recognizes the first eight amino acids on the fJ-chain of the haemoglobin, and therefore will not recognize HbS (fJ6 g1u~val) or HbC (fJ6g1u~lys) where the amino acid change is on position six. A low result will be produced when an abnormal haemoglobin is present, and this effect must always be borne in mind when reviewing low HbA 1c results obtained using this method.
Although reagents for this method are competitively priced, the method can be labour intensive. Instruments for measuring the final colour can be supplied by the manufacturer, but many laboratories already possess a microtitre plate reader. By this method 88 samples can be analysed in approximately 2 h, and using pipetting stations the method can be semiautomated. As such this method is more suited for batch analysis of samples. lmmunoturbidimetry A HbA 1c method based on homogeneous immunoassay (Tina-Quant) has been introduced by Boehringer Mannheim (Lewes, UK). The assay is based on the photometric determination of total haemoglobin and the immunoturbidimetric determination of HbA)c. An antibody, recognizing the first four amino acids and glucose on the fJ-chain of haemoglobin, reacts with HbA lc to give a soluble immune complex. Polyhaptens then bind to excess antibodies and the resulting agglutinated complexes are measured turbidimetrically at 340 nm (Fig. 3) . The agglutinated complex is inversely proportional to the analyte concentration in the sample. Total haemoglobin is measured simultaneously by photometry at 570 nm. The method was designed for use on Hitachi analysers (Boehringer Mannheimj." but has been adapted for use on method; laboratories should investigate this interference themselves. Both immunoturbidimetric methods are highly automated, and costs mirror the fact that they are not labour intensive. The methods can be adapted, to differing degrees, for use on a variety of analysers; but it should be recognized that the laboratory must possess, or be able to acquire, an analyser capable of running these methods.
Immunoassay HhA Ie Analyser (DCA 2000™)
The DCA 2000™ analyser (Bayer Diagnostics, Basingstoke, UK) measures the concentration of HbA 1c and the concentration of total haemoglobin; the ratio of the two is displayed as %HbA le. The analyser utilizes a cartridge which contains all the necessary reagents, as described below.
Total haemoglobin is estimated using potassium ferricyanide, which oxidizes the haemoglobin to methaemoglobin which, in turn, complexes with thiocyanate. The resulting thiocyan-methaemoglobin complex is measured at 531 nm. The extent of colour formation is proportional to the concentration of total haemoglobin in the sample.
Haemoglobin Ale is estimated using a method based on inhibition of latex agglutination. A synthetic polymer containing multiple copies of the immunoreactive portion of HbA 1e causes agglutination of latex particles coated with HbA le specific mouse monoclonal antibody. Agglutination increases scattering of light, which is measured as an increase in absorbance at 531 nm. Haemoglobin Ale in whole blood specimens competes for the limited number of antibody-latex binding sites, causing an inhibition of agglutination and a decreased scattering of light. The HbA le concentration is quantified using a calibration curve, previously programmed into the analyser, relating absorbance to HbA le concentration.
This analyser has been designed specifically for use in the clinic. Finger prick samples are used. Specimens are analysed singly using a disposable cartridge and results are available in 9 min. The performance of this analyser was found to display good withinand betweenbatch precision and show good correlation with established methods in use in clinical laboratories.>' The antibody used has been raised against the first three amino acids and the attached glucose.
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SPECIMENS FOR MEASUREMENT OF GLYCATED HAEMOGLOBIN
All methods require only very small volumes of red cells, the largest volume required (100 J-LL red cells) is for affinity chromatography. With newer methods sample volumes are sufficiently small that finger prick testing can be used. There are no special collection conditions; the patient does not have to be fasting. Blood is usually collected into EDTA but may also be collected into heparin and fluoride oxalate. The latter anticoagulant must be avoided if the method used relies on charge separation. Many methods utilize washed red cells thereby eliminating the affect of bilirubin and lipaemia, which may interfere in methods that use whole blood.
Schiff base, the intermediate fraction formed during the glycation process, is rapidly formed (hours) and is readily reversible following a lowering of the blood glucose. This labile fraction will slowly (days) undergo an Amadori rearrangement to form a stable (almost irreversible) glycated haemoglobin. A transient increase in blood glucose will result in an increase in this labile fraction. For the glycated haemoglobin results to be representative of long-term glycaemic control, this interfering Schiff base must be removed before analysis as this fraction interferes with methods relying on charge separation. Removal of this fraction can be achieved by incubation in saline overnight. However, most methods that suffer from this interference provide a means by which this fraction can be removed, e.g. a haemolysing solution containing a glucose trap that has the effect of reversing the initial glycation reaction within a short time period (typically less than 30 min).
Little and co-workers!' have investigated collecting blood samples onto filter paper that had previously been soaked in a glucose oxidase solution. These workers used the glucose oxidase-containing reagent to reduce free glucose in an attempt to inhibit the rapid in vitro glycation of haemoglobin during drying. The pre-treatment of the filter paper substantially limited, but did not completely inhibit, the increase in glycated haemoglobin over time.
Their results demonstrated that the measured glycated haemoglobin increased from day I to day 14, but there was no further increase up to day 21. Using a standard storage time of 14 days, the reference range for non-diabetics [mean (2SD)] was found to be 8·66 ± 1·60% John (n = 26) for filter paper samples compared to 5·83 ± 1·48% (n = 28) for haemolysates analysed directly by affinity chromatography. The high degree of correlation, between samples collected onto filter paper and the corresponding blood sample, that had been frozen, led the authors to conclude that, with limitations, this form of sample collection may be useful. A different reference range would have to be used for assessment of results.
Storage conditions
Reports on stability of samples for glycated haemoglobin analysis differ. Sample stability may also be method dependent. Papadea and co-workers52 investigated the affect of storage conditions on ion exchange and affinity chromatographic assays. They reported a significant increase in HbA) with time of storage (6 days at 4°C or 24°C with 5 mmol/L or 30 mmol/L glucose), whilst HbA lc and glycated haemoglobin showed no significant change. Gruber and Koets 28 reported that whole blood stored at 4°C showed significant increases in HbA1(a+b) after 24 h and in HbA 1c after 48 h; much of this increase, which may be as much as three-to fourfold by 50 days, is due to elevations in 'HbA l d ' which elutes with HbA1(a+b) in ion exchange mini columns.P An appropriate dilution ofhaemolysate (50 JlL haemolysate in 3 mL diluent) and addition of 25 rnmol/L cysteine renders both HbA1(a+b) and HbA]c stable for up to 5 weeks at 4°c. 54 Not all investigators report instability of glycated haemoglobin in whole blood samples. Schellekens and co-workers reported that hepar-inized blood is stable for 3 days at 4°C,55 others report stability for 7 days56,57 and even up to 4 weeks. 58.59 It must be noted that storage in a glucose-free solution will eliminate the affect of the labile Schiff base.
If specimens are haemolysed as soon as possible, the haemolysates are stable for at least 1-2 weeks depending on the method used. Investigators must assess sample stability in their own laboratory, especially if long-term storage is to be contemplated.
IMPRECISION
The National Diabetes Data Groups" have suggested targets for within-and between-batch imprecision of 5%, CV for HbA lc' Based on within-subject variation and modelling of strategies for the use of HbA lc in clinical practice, other investigators" have suggested a maximum CV of 5% with an optimum CV of around 2%. Most methods introduced into clinical practice in the last 5 years are capable of achieving imprecision approaching these recommendations ( Table 2) .
ACCURACY
Due to the range of different glycated fractions measured by the various methods and the lack of a recognized standard, it is impossible to define accuracy. An International Federation of Clinical Chemistry (lFCC) working party is at present investigating the production of a primary reference material for HbA 1c, also a reference method is being developed based on HPLC-MS, this method will hopefully be established in a number of reference laboratories by mid 1997. At present performance in external quality assessment can only be used to assess precision of a specific method within a laboratory or bias of one method from another. There are a number of interfering conditions and substances that may potentially affect glycated haemoglobin estimation (Table 3) . Interferences may either affect the assay directly or have a physiological origin.
Acute changes in blood glucose concentration
Haemoglobin glycation rate is a function of the concentrations of reactants, glucose and haemoglobin. Haemoglobin concentrations remain relatively constant in most individuals, so fluctuations in HbA lc concentrations primarily reflect long-term fluctuations in glucose concentrations. Transient acute changes in glucose concentration should have little effect on HbA l c concentrations. However, several studies have documented that a variable proportion of the HbA 1c , as measured by rapid physical separation methods, appears to consist of a labile Schiff base. This fraction is responsive to short-term fluctuations in blood glucose. Dunn and coworkers'" described correlations between HhA, concentrations and parameters of glycaemia (mean capillary glucose concentration, glycosuria and serum triglycerides) over an 8-week period. The week-8 Hb A, concentrations showed a poor correlation with week-I glycaemic parameters. Glycaemic parameters for later weeks showed better correlation, suggesting that HbA j responds acutely to blood glucose changes. Increased HbA 1c was showns! when whole blood from diabetics and non-diabetic controls was incubated with glucose for 7 h, and the increases were greater with higher concentrations of glucose. Furthermore, measurable increases in HbA j c were seen at 6 and 10 h when two diabetic patients were removed from control by 'biostator' artificial pancreas and infused intravenously with glucose. A third patient, who was placed on biostator control after a 24-h period of insulin withdrawal, showed measurable declines in HbA lc over the l2-h period following restoration of good glycaemic control.
The above studies 62 • 63 primarily used variants of mini-column ion exchange chromatography for estimating HbA lc ' Leslie and co-workers'< studied a group of eight newly diagnosed insulin-dependent diabetics over a 3-week period, and estimating HbA 1 by a macrocolumn technique, showed a decrease in HbA 1c over weeks, not days. Goldstein and co-workers.v using HPLC methodology, showed that diabetic patients, but not normal controls, exhibited increases in HbA 1c 2 h after a test meal, and that increases in HbA lc occurred rapidly and reversibly when red blood cells from controls and diabetics were incubated with glucose or saline. These authors concluded that HbA j c exists in two chromatographically indistinguishable forms, which they suggested might be the labile Schiff base and the stable ketoamine. The red blood cell incubation experiments led them to the conclusion that 10%-20% of the total HbA j c is labile in both normals and diabetics, and that this labile fraction correlates with plasma glucose at the time of sampling. Saline dialysis of haemolysates for 48 h completely removed this labile fraction, but this was incomplete after 18 h dialysis. They cautioned that columns for fast haemoglobin may not accurately reflect the stable form of HbA\c, even after dialysis, and that recent changes in blood glucose may change HbA 1c values by 1-2%. Widness and co-workers's suggested that the longer column and slower flow rates of the macrocolumn procedure favour the dissociation of labile aldimine (Schiff base) linkages, and that for short-column methods, dialysed haemo-Iysates may better reflect long-term glucose control. The finding that rapid increases in HbA lc, as measured by chromatography, were not seen with a thiobarbituric acid chemical method, gave further support to the nonketoamine nature of the rapidly glycating fraction.s? Mortenson'" reported that the Schiff base 'intermediate' could be separated from stable HbA lc by isoelectric focusing. The intermediate band disappeared when erythrocytes were incubated overnight in saline. The concentrations of intermediate were reported to parallel concentrations of blood glucose, but not HbA 1c, in three patients during a 5-h postprandial period. The correlation of intermediate concentration expressed as a percentage of total haemoglobin, with blood glucose was excellent (r = 0'95), and incubation of erythrocytes and glucose yielded similar results (r = 0,98). Nathan'" reported that the labile fraction accounted for 2%-3,5% of HbA 1 in normal red cells and 7%-9'5% in diabetic red cells when measured by HPLC or agar electroendosmosis.
A number of techniques have been proposed for the elimination of the Schiff base from the specimens before analysis. The simplest, but most time consuming method is to incubate red cells in isotonic saline either overnight at room temperature, or for 6 h at 37"C. In a rapid chemical method for aldimine elimination, red cells are incubated for 30 min at 38°C with 30 mmol/L semicarbazide and 12 mmol/L alanine, pH 5,0. 70 After incubation, the red cells are separated by centrifugation, the supernatant aspirated and the packed cells prepared for assay. Yet another method simply lyses red cells with 0·05 mol/L potassium bithalate buffer, pH 5·0, making use of the instability of the Schiff base adduct in acidic solution." At this pH, dissociation of the Schiff base reaches completion during sample preparation.
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Schiff base interferes with methods relying on charge separation, but is reported not to affect affinity chromatography'? or immunoassay."
Altered red cell survival
Disorder that result in shortened red cell survival will result in decreased values for glycated haemoglobin, e.g. haemolytic anaemia. Blood transfusion will bias the per cent glycated haemoglobin towards that of the transfused haemoglobin; this is particularly relevant as transfusion bags contain a high glucose concentration. Increased glycated haemoglobin concentrations accompany increased red cell survival after splenectomy.P
Abnormal haemoglobins
The presence of HbF,74,75 HbS,76-78 HbC79 and other abnormal haemoglobinsv'-" have been reported to affect glycated haemoglobin analysis. Engback and co-workers.V using nondiabetic patients with abnormal haemoglobins, investigated the effect of these haemoglobins on ion exchange chromatography, HPLC and EIA. These authors report that any haemoglobin with different chromatographic mobility will interfere with the measurement. HbF 74,75 and some other variant haemoglobinsw-" co-chromatographed with HbA Ic , and gave falsely high HbA lc results. In addition, they found that glycated HbS did not co-chromatograph with HbA 1c, causing decreased results of glycated haemoglobin by HPLC for patients with the HbS-trait.
John and co-workers" investigated the effect of abnormal haemoglobins on the EIA method and compared results with those obtained by HPLC. This method specifically measures haemoglobin A glycated at the N-terminal valine of the fJ-chain (with the epitope being the first eight amino acids on that chain). When no HbA was present in the sample (e.g. HbS/HbC) no HbA Ic could be measured by either method. When a combination of HbA and a variant was analysed by this method, low HbA\c results were obtained for HbA/HbC compared to HPLC, but results for the HbA/HbF combination show similar HbA\c results on the two assay systems. As the effect of abnormal haemoglobins on a method is constant, provided there is no change in the percentage of the variant, then once a value for HbA lc has been established, this will act as a baseline for future measurements.
Affinity chromatography is the only analytical system that is unaffected by the presence of abnormal haemoglobins.P The affinity gel detects the glucose bound to haemoglobin, the type of haemoglobin (or indeed the type of protein) does not affect the separation. If there is a complex mix of haemoglobin variants, then this assay must be the method of choice, but it must be remembered that what is measured by this method cannot be directly related to results obtained by other systems.
Jaundice and hyperlipidaemia
Severely icteric specimens may give falsely elevated HbA I values with methods relying on charge separation if whole blood haemolysates are used, since bilirubin migrates with the fast haemoglobin and absorbs at the detecting wavelength. Lactescent plasma due to hyperlipidaemia can also cause false elevation of HbA 1 , since lactescence elutes in the first HbA I fraction and absorbs at 415 nm. The problem could be magnified if analysis is performed on postprandial samples. Since hyperlipidaemia is a relatively common finding in diabetics, this limitation should be appreciated.
Acetylation by aspirin
Aspirin modifies several sites, presumably lysines, on both the IX-and p-chains of HbA. Acetylation of lysine residues with aspirin confers a negative charge on the modified protein. The modified haemoglobin has altered electrophoretic and chromatographic (ion exchange) properties, migrating ahead of HbA o like HbA!. Patients on long-term high-dose aspirin therapy may have a twofold increase in the modified haemoglobin. Also, a linear increase in HbA! has been demonstrated with increasing aspirin concentration and time of incubation of red cells, haemolysate or purified HbA o . It is likely, therefore, that patients receiving high dose aspirin will demonstrate increased concentrations of HbA I .
Carbamylation by uraemia in renal failure
Elevated concentrations of both HbA I and HbA1c-like haemoglobins have been reported in patients with renal failure. M 4--M6 In renal failure, significant numbers of patients have impaired glucose tolerance, and those on dialysis are usually dialysed against a fluid with a high glucose content. It is likely that some increase in HbA 1 will occur due to the presence of the increased glucose concentration (although patients in chronic renal failure tend to have a shortened red cell survival). However, it appears that most of the increase in HbA! in uraemic patients is due to carbamylation of haemoglobin Glycated haemoglobin analysis 27 with cyanate and ammonia. Cyanate appears to react with protein amino groups, preferentially but not exclusively with IX-amino groups. The mean concentration of HbA], determined by Bio-Rex 70 column chromatography, was 7·12% in the control group, 8·79% in the dialysis patients and 10·78% in stable uraemic patients."
The increase in HbA] was found to be due entirely to the increase in HbA!(a+b) fraction. It has been demonstrated that results of HbA! were significantly different, when analysed by electroendosmosis, in patients pre-and postdialysis, whereas when glycated haemoglobin was estimated by affinity chromatography on the same patients no difference was demonstrated." Therefore, in uraemic patients HbA! values, obtained using methods relying on charge separation, must be interpreted with care. It is also worth noting that patients with renal failure are often predisposed to anaemia with altered red cell survival, which as stated above will also have an effect on the level of glycated haemoglobin.
CALIBRATION AND QUALITY ASSURANCE
Glycated haemoglobin is usually reported as a percentage of total haemoglobin. In many methods the inherent colour of the haemoglobin is used to calculate this directly from the separated glycated and non-glycated fractions. This should be satisfactory where there is a complete separation of the fractions that is unaffected by environmental conditions (such as temperature), and where the colorimetric measurements are reliable. However, some methods, including ion-exchange chromatography, are affected greatly by temperature and other factors, and the use of a calibration material (one with a stable known concentration) to correct for these, is essential. In other cases, such as immunoassay, a calibration material is required to obtain a result. It should also be noted that EIA procedures measure the concentration of HbA lc but report in percentage terms, with reference to an assumed total haemoglobin concentration. Since calibration materials do not show the same properties as fresh clinical specimens they may be used only for the method for which they were designed. Similarly, quality control materials will have method-dependent assigned values, even for the same species (HhA], HbA lc or GHb). At present there is a dearth of good John material available for calibration or internal quality control of glycated haemoglobin assays. A calibration material should have a stable glycated haemoglobin concentration and the haemoglobin itself should be stabilized. The material should be human in nature and, if lyophilized, the reconstitution buffer must be a protein matrix to enable it to be used on all methods. The value should be assigned by a reference HPLC method optimized to separate HbA\c as a discrete peak with baseline separation from HbAo, HbA 1a and HbA 1b. Even if these practical problems can be overcome, however, it is not possible or permissible to use a calibration material to interconvert results for HhA], HbA lc and glycated haemoglobin, since the relationships between these vary among clinical specimens. The IFCC is actively working towards producing such a calibration material.
For external quality assessment the situation is somewhat better. The UK National External Quality Assessment Scheme (NEQAS) was started in 1984, and uses human blood specimens derived from normal and diabetic volunteer donors. Every 2 months three specimens are distributed to participating laboratories for analysis. The results received are compared with overall and method-related targets for the relevant species (HbAj, HbA 1c, or glycated haemoglobin). Table 2 gives illustrative data from the UK NEQAS. Overall, the scheme provides participating laboratories with an independent and objective assessment of their performance, constituting an educational stimulus to improvement. All laboratories offering an analytical service should participate.
CONCLUSION
In the two decades since the introduction of glycated haemoglobin analysis into the clinical laboratory, methods have greatly improved, although only recently has there been a move towards standardization of these methods or, indeed, of the results produced. It is likely that methods will be standardized on HbA 1c, although there appears to be no clinical advantage in measuring this fraction over HbA 1 or glycated haemoglobin. A number of HPLC methods use a calibrant to correct the results obtained, resulting in improved between laboratory agreement (Table 2) . Immunoassay requires calibration, but no internationally recognized standard has been produced. At present, all available calibration and quality control materials have method dependent values. The lack of agreed standardization has resulted in similar methods producing significantly different results on the same material used for quality assessment.
The quality of peak separation with optimized HPLC methods has considerably improved, as has the quality of integration of the peaks obtained. Dedicated HbA 1c HPLC analysers have shortened the analysis time to less than 5 min. Unfortunately, this requirement for speed has resulted in incomplete separation of the haemoglobin peaks: in many cases the peak value is calculated by computer model. The immunoassay method, which uses calibrators assigned by HPLC, is found to display results considerably lower than those produced with dedicated HbA lc HPLC analysers.
The question of terminology should also be addressed in describing what is being measured; can a non-ion exchange method like immunoassay really measure HbA 1c ? The choice of terminology in this case is unfortunate, but the method does measure haemoglobin glycated at the N-terminal valine and is calibrated using calibrants assigned by HPLC. This is not the case for the Vision and IMX analysers which measure glycated haemoglobin by affinity separation. Results are corrected using calibrants assigned by HPLC and reported as HbA lc' This is claimed to be valid as results for glycated haemoglobin correlate with HbA lc results. A similar situation could be claimed for protein determination since albumin results correlate well with protein results. However no one would attempt to correct albumin results via a correlation graph and report total protein. In both cases these are different species, and should be treated as such.
Looking into the future, the current trend for ever-increasing numbers of requests will result in further automation, with instruments performing significant amounts of sample pre-treatment. The recent introduction ofmonoclonal antibodies will undoubtedly result in the development of assays suitable for use on routine clinical chemistry analysers. A basic requirement for future analysers is the development of a recognized, method independent standard material. 19 
